All In Biotech

Drug Trial Radar · NCT07893171

Study of CM529D1 in Participants With Advanced Solid Tumors

A Multicenter, Open-Label, Phase I/Ⅱ Clinical Study to Evaluate CM529D1 in the Treatment of Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

128

Planned (sponsor's estimate)

Start

Nov 27, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Oct 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is interventional study to evaluate the safety and tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of CM529D1 in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • CM529D1Biological

    CM529D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.

  • CM529D1Biological

    CM529D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(RP2D).

  • CM529D1Biological

    CM529D1 will be administered intravenously once every 3 weeks (Q3W) in different types of solid tumor cohorts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT)-Phase I dose escalationTime frame: First cycle (21 days)
  2. Incidence of adverse events (AEs), serious adverse events (SAEs), and specific laboratory abnormalities-Phase I dose escalationTime frame: Through study completion, an average of 2 years
  3. The Recommended Phase 2 Dose (RP2D)Phase I dose expansionTime frame: Through study completion, an average of 2 years
  4. Objective response rate (ORR)-Phase IITime frame: Through study completion, an average of 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.